1-5 of 5
Mark Levis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Mark Levis, Alexander Perl, Gary Schiller, Amir T. Fathi, Gail Roboz, Eunice S. Wang, Jessica Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael Kurman, Catherine Smith
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2527–2535.
https://doi.org/10.1182/bloodadvances.2023010619
Published: 2024
Includes: Supplemental data
Journal Articles

Gilteritinib: potent targeting of FLT3 mutations in AML

Clinical Trials & Observations
Mark Levis, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1178–1191.
https://doi.org/10.1182/bloodadvances.2019000174
Published: 2020
Journal Articles

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3052–3061.
https://doi.org/10.1182/bloodadvances.2019000197
Published: 2019
Includes: Supplemental data
Journal Articles

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Laura K. Schoch, Kenneth R. Cooke, Nina D. Wagner-Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2226–2229.
https://doi.org/10.1182/bloodadvances.2018019208
Published: 2018
Journal Articles

The current therapeutic landscape of FLT3 inhibitors

Mark Levis
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1944.
https://doi.org/10.1182/bloodadvances.2017007682
Published: 2017
Includes: Supplemental data